The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

24 Sep 2007 08:00

ViaLogy PLC24 September 2007 24th September 2007Embargoed until: 0800hrs ViaLogy appoints Dr. Robert Dean as CEO ViaLogy PLC (VIY), the AIM-quoted technology company that is the leadinginnovator of network-centric, real time signal processing platforms for sensorapplications, today announces the appointment of Dr. Robert W Dean as Presidentand Chief Executive Officer (CEO) of ViaLogy LLC, its wholly-owned Americansubsidiary company based in Pasadena, California. Dr. Dean, who has served as anon-executive director on the ViaLogy PLC board since it joined AIM last year,will become an executive director on the main board. Dr. Dean moves to ViaLogy from the Science Applications InternationalCorporation (SAIC), a global systems and technical services company where he wasSenior Vice President, Corporate Market Development. Previously he has heldsenior management and board positions, concentrating on business development andstrategic planning, with such international organisations as Boeing, LockheedMartin, United Space Alliance, MacDonald Dettwiler, Electro Optic Systems, theRand Corporation and the Ball Corporation. During the President Reagan's term Dr. Dean served as Special Assistant to thePresident and was Senior Director of the National Security Council. He was alsothe senior White House executive responsible for high technology issues. Duringhis distinguished career he has held senior positions with the CentralIntelligence Agency and the US Department of State. He has received numerousawards for public service including the Grand Service Cross of the FederalRepublic of Germany, which is the highest civilian honour awarded to a foreigncitizen. "We are delighted that Bob Dean has agreed to accept the most senior managementposition with ViaLogy," said executive chairman, Terry Bond. "He has theexperience and vision that makes him the ideal person to lead us at thisexciting time in the company's development. Our technology has now beenvalidated for a number of important industrial applications. Next month,October, we will be announcing and demonstrating ViaLogy's commercial productsfor defence, oil and gas and enterprise management and business continuityapplications." Said Dr. Dean: "During the time I have served as a non-executive director ofViaLogy I have been very impressed by the potential of the company's technologyand products and the abilities of its staff. I look forward to growing the salesand marketing organisation and deploying ViaLogy products for partners andcustomers in the US and globally. "I am confident that ViaLogy will achieve the success in the market place thatits unique technology deserves." End For further information please contact: ViaLogyTerry Bond, Chairman +44 (0)1235 834734 or 07860 842756 Seymour Pierce (Broker)Mark Percy, Nominated Adviser +44 (0)20 7107 8032 Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications. ViaLogy is currently deploying and designingcomputational systems, powered by its patented technologies, for applications inlife sciences, public safety and security, surveillance, defence andgeoseismology. Vialogy focuses on market driven problems where automation,timeliness, quality and reliability of information processing are essential.ViaLogy's core competency incorporates rapidly and accurately detecting weaksignals buried in high noise background and clutter. This technology can beemployed to solve problems involving sensor integration and information overloadchallenges involving video, telephony and control sensors, as well as forenhancement of numerous signal processing applications. For more information,visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.